Provided by Tiger Trade Technology Pte. Ltd.

Immuneering Corp

5.02
+0.16003.29%
Post-market: 5.050.0300+0.60%19:49 EDT
Volume:7.29M
Turnover:36.45M
Market Cap:324.14M
PE:-3.94
High:5.03
Open:4.81
Low:4.76
Close:4.86
52wk High:10.08
52wk Low:1.10
Shares:64.57M
Float Shares:54.41M
Volume Ratio:5.77
T/O Rate:13.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2729
EPS(LYR):-1.2729
ROE:-43.12%
ROA:-26.07%
PB:1.48
PE(LYR):-3.94

Loading ...

Leerink Partners Initiates Immuneering at Outperform With $15 Price Target

MT Newswires Live
·
Oct 31, 2025

Immuneering Initiated at Outperform by Leerink Partners

Dow Jones
·
Oct 31, 2025

Immuneering price target raised to $12 from $10 at Mizuho

TIPRANKS
·
Oct 29, 2025

Director’s Bold Move: Immuneering Stock Purchase Signals Confidence

TIPRANKS
·
Oct 08, 2025

Immuneering Director Peter Feinberg Reports Acquisition of Common Shares

Reuters
·
Oct 07, 2025

Immuneering Chief Legal Officer Michael Bookman Reports Acquisition of Common Shares

Reuters
·
Oct 02, 2025

Mizuho Securities Remains a Buy on Immuneering (IMRX)

TIPRANKS
·
Oct 02, 2025

Director’s Bold Move: Major Investment in Immuneering Stock!

TIPRANKS
·
Oct 01, 2025

Immuneering Director Peter Feinberg Reports Acquisition of Common Shares

Reuters
·
Sep 30, 2025

Immuneering Price Target Maintained With a $11.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 30, 2025

Immuneering’s Promising Phase 2a Data and Safety Profile Drive Buy Rating

TIPRANKS
·
Sep 30, 2025

Immuneering Corporation Presents Promising Survival Data for Atebimetinib Plus Chemotherapy in First-Line Pancreatic Cancer

Reuters
·
Sep 29, 2025

Immuneering Corporation's (NASDAQ:IMRX) last week's 13% decline must have disappointed individual investors who have a significant stake

Simply Wall St.
·
Sep 27, 2025

Immuneering Announces Promising Overall Survival Data from Phase 2a Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients

Reuters
·
Sep 27, 2025

Immuneering to Discuss Recently Announced Overall Survival Data From Phase 2a Clinical Trial of Atebimetinib + Mgnp in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

THOMSON REUTERS
·
Sep 27, 2025

Chardan Raises Price Target on Immuneering to $20 From $13, Keeps Buy Rating

MT Newswires Live
·
Sep 26, 2025

Piper Sandler Sticks to Its Buy Rating for Immuneering (IMRX)

TIPRANKS
·
Sep 26, 2025

U.S. RESEARCH ROUNDUP-Carmax, Mirion Technologies, Valmont Industries

Reuters
·
Sep 26, 2025

Immuneering Corp : Chardan Capital Markets Raises Target Price to $20 From $13

THOMSON REUTERS
·
Sep 26, 2025

Immuneering Is Maintained at Outperform by Oppenheimer

Dow Jones
·
Sep 25, 2025